Published in N Engl J Med on November 15, 2014
HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A | NCT00283686
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int (2015) 1.50
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2015) 1.40
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2015) 1.05
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2015) 1.05
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2015) 1.04
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol (2016) 1.02
Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression. Nephrol Dial Transplant (2015) 0.94
Molecular pathways and therapies in autosomal-dominant polycystic kidney disease. Physiology (Bethesda) (2015) 0.93
Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function. Ther Adv Drug Saf (2015) 0.87
Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease. EBioMedicine (2016) 0.86
Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model. FASEB J (2015) 0.86
A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol (2015) 0.84
A quest--halting the progression of autosomal dominant polycystic kidney disease. N Engl J Med (2014) 0.82
Semiautomated Segmentation of Polycystic Kidneys in T2-Weighted MR Images. AJR Am J Roentgenol (2016) 0.81
Rationale, design and objectives of ARegPKD, a European ARPKD registry study. BMC Nephrol (2015) 0.80
The Treatment of Autosomal Dominant Polycystic Kidney Disease. Dtsch Arztebl Int (2015) 0.80
Diet and polycystic kidney disease: A pilot intervention study. Clin Nutr (2016) 0.79
The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. Nat Rev Nephrol (2015) 0.79
Nephrology research-the past, present and future. Nat Rev Nephrol (2015) 0.79
The importance of total kidney volume in evaluating progression of polycystic kidney disease. Nat Rev Nephrol (2016) 0.78
Hypertension in Chronic Glomerulonephritis. Electrolyte Blood Press (2015) 0.78
Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963-2014). Popul Health Metr (2017) 0.78
Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int (2017) 0.78
Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials. Oncotarget (2015) 0.77
The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatr Nephrol (2016) 0.76
Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol (2016) 0.76
Autosomal dominant polycystic kidney disease in children. Curr Opin Pediatr (2015) 0.76
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring. J Vis Exp (2015) 0.76
Renal volume and cardiovascular risk assessment in normotensive autosomal dominant polycystic kidney disease patients. Medicine (Baltimore) (2016) 0.75
Decade in review-polycystic kidney disease: Slowing progression of autosomal dominant polycystic kidney disease. Nat Rev Nephrol (2015) 0.75
Stop chronic kidney disease progression: Time is approaching. World J Nephrol (2016) 0.75
An association between autosomal-dominant polycystic kidney disease and the risk of acute myocardial infarction in Asian population - results of a nationwide study. Oncotarget (2016) 0.75
Experiences and Perspectives of Polycystic Kidney Disease Patients following a Diet of Reduced Osmoles, Protein, and Acid Precursors Supplemented with Water: A Qualitative Study. PLoS One (2016) 0.75
Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease. PLoS One (2017) 0.75
Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Can J Kidney Health Dis (2017) 0.75
Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int (2016) 0.75
Anthropometric and Metabolic Risk Factors for ESRD Are Disease-Specific: Results from a Large Population-Based Cohort Study in Austria. PLoS One (2016) 0.75
Heterotrimeric G protein signaling in polycystic kidney disease. Physiol Genomics (2016) 0.75
Decreased Polycystin 2 Levels Result in Non-Renal Cardiac Dysfunction with Aging. PLoS One (2016) 0.75
The Authors Reply. Kidney Int (2015) 0.75
Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus. Can J Kidney Health Dis (2017) 0.75
Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan. CEN Case Rep (2015) 0.75
Clinical Manifestation and Management of ADPKD in Western Countries. Kidney Dis (Basel) (2016) 0.75
Clinical Trials in Pediatric Autosomal Dominant Polycystic Kidney Disease. Front Pediatr (2017) 0.75
Hypokalemic Hypertension Leading to a Diagnosis of Autosomal Dominant Polycystic Kidney Disease. Electrolyte Blood Press (2016) 0.75
Polycystin 2-dependent cardio-protective mechanisms revealed by cardiac stress. Pflugers Arch (2017) 0.75
Kidney dysfunction following adrenalectomy in autosomal dominant polycystic kidney disease complicated with primary aldosteronism: A case report. Exp Ther Med (2017) 0.75
Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys. J Digit Imaging (2017) 0.75
Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol (2017) 0.75
Random-effects models for longitudinal data. Biometrics (1982) 54.17
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int (2009) 3.66
Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med (2008) 3.53
Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int (1992) 2.89
The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med (1990) 2.82
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis (2011) 2.05
Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int (2003) 1.65
Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol (2002) 1.63
The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol (2010) 1.59
Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol (1995) 1.58
Angiotensin II activation of cyclin D1-dependent kinase activity. J Biol Chem (1996) 1.51
Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int (1990) 1.36
MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol (2009) 1.24
Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol (2014) 1.24
Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark. Clin J Am Soc Nephrol (2010) 1.19
Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int (1992) 1.18
Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int (2011) 1.13
The anatomy of the renin-secreting cell in adult polycystic kidney disease. Kidney Int (1988) 1.10
Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol (2007) 1.09
Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol Dial Transplant (2011) 1.06
Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc (1991) 1.01
Hypertension and autosomal dominant polycystic kidney disease. Am J Kidney Dis (2011) 0.95
Aldosterone as a renal growth factor. Steroids (2009) 0.95
Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease. Pediatr Nephrol (2010) 0.95
Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis (1994) 0.94
Epidemiology, outcomes and validation of RIFLE and AKIN criteria in acute kidney injury (AKI) in critically ill patients: Indian perspective. Ren Fail (2014) 0.93
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med (2003) 23.33
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Autosomal dominant polycystic kidney disease. Lancet (2007) 8.55
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Surgery versus nonsurgical treatment of lumbar spinal stenosis: a randomized trial. Ann Intern Med (2015) 6.66
Progress and prospects in rat genetics: a community view. Nat Genet (2008) 6.01
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord (2004) 4.83
Polycystic kidney disease. Annu Rev Med (2009) 4.78
The effect of social desirability and social approval on self-reports of physical activity. Am J Epidemiol (2005) 4.65
The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet (2002) 4.54
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med (2003) 3.78
Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int (2009) 3.66
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 3.26
The transmembrane protein meckelin (MKS3) is mutated in Meckel-Gruber syndrome and the wpk rat. Nat Genet (2006) 3.19
Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med (2004) 3.09
Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol (2006) 3.02
Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int (2009) 2.99
Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol (2006) 2.95
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol (2005) 2.92
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension (2012) 2.86
Obesity and physical inactivity in rural America. J Rural Health (2004) 2.84
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol (2007) 2.71
Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology (2006) 2.68
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med (2008) 2.65
Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum Mol Genet (2003) 2.55
Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int (2004) 2.55
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int (2012) 2.39
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) (2006) 2.34
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int (2003) 2.32
Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol (2008) 2.26
Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem (2004) 2.26
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg (2009) 2.23
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2006) 2.21
Person and place: the compounding effects of race/ethnicity and rurality on health. Am J Public Health (2004) 2.14
Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med (2011) 2.14
Characterization of PKD protein-positive exosome-like vesicles. J Am Soc Nephrol (2009) 2.13
Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int (2005) 2.13
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J (2009) 2.12
Sitagliptin--another option for managing type 2 diabetes in dialysis patients? Am J Kidney Dis (2013) 2.05
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Loss of polycystin-1 in human cyst-lining epithelia leads to ciliary dysfunction. J Am Soc Nephrol (2006) 1.95
Total and intraabdominal fat distribution in preadolescents and adolescents: measurement with MR imaging. Radiology (2007) 1.92
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens (2010) 1.90
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol (2010) 1.89
Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology (2003) 1.80
Coronary angiography predicts improved outcome following cardiac arrest: propensity-adjusted analysis. J Intensive Care Med (2009) 1.76
Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest (2012) 1.74
Risk of hand or glove contamination after contact with patients colonized with vancomycin-resistant enterococcus or the colonized patients' environment. Infect Control Hosp Epidemiol (2008) 1.74
Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol (2003) 1.74
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging (2008) 1.72
Human ADPKD primary cyst epithelial cells with a novel, single codon deletion in the PKD1 gene exhibit defective ciliary polycystin localization and loss of flow-induced Ca2+ signaling. Am J Physiol Renal Physiol (2006) 1.72
Follow-up of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int (2004) 1.71
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 1.69
Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica (2008) 1.67
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension (2008) 1.66
Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology (2013) 1.66
A complete mutation screen of the ADPKD genes by DHPLC. Kidney Int (2002) 1.66
Automated clinical reminders for primary care providers in the care of CKD: a small cluster-randomized controlled trial. Am J Kidney Dis (2011) 1.66
Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. Clin J Am Soc Nephrol (2010) 1.65